« Return to News | CROs/Service Providers

Almac doubles analytical capacity, adds 10 jobs

Wednesday, February 15, 2012 02:59 PM

Almac is doubling its analytical capacity at its North American headquarters in Souderton, Penn., increasing the number of employed scientists from 10 to 20.

The 240,000-square-foot facility, built on a 40-acre site, delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients. The facility boasts state-of-the-art analytical labs, supplementing facilities in the U.K.

The additional lab investment will offer new support in the form of polymorph and salt screening, solid form development and the latest bathless dissolution apparatus for rapid and efficient comparative dissolution studies. The last will provide maximum flexibility for developing, validating and running assay, dissolution and stability methods, further complementing the large capacity stability chambers which provide all the required ICH stability conditions.

In addition, the lab will continue to provide support for clinical packaging operations and stand-alone analytical services.

The analytical facility complements Almac’s specialty capabilities, including biocatalysis, radiolabelling, and peptide and protein synthesis. These services are all part of Almac’s comprehensive drug development services, including API and drug product development and GMP manufacture.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.